A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of AJ302-IM in Healthy Volunteers Via Intramuscular Injection
Latest Information Update: 09 Oct 2024
At a glance
- Drugs AJ 302 (Primary)
- Indications Chemotherapy-induced damage
- Focus Adverse reactions
- Sponsors AnnJi Pharmaceutical
Most Recent Events
- 09 Oct 2024 New trial record